huE9E777 Frozen Validation Report
342 PRS models · 1,636 protein predictions · 140 candidate variants. This static snapshot is generated from the public report JSON artifact.
Overview-first report: suggested next steps are shown before technical PRS and protein tables. Genetic evidence is not diagnostic by itself.
Clinical Variant Status
✓No confirmed pathogenic
Cardiovascular lipid and blood-pressure context
near-term focus
Heart and lipid evidence is mixed: there is a clear coronary and lipid-review signal, but also favorable cholesterol, clotting, heart-failure, and heart-structure context.
Full explanation
Your heart-related genetics do not point in one simple direction. There is a meaningful signal around coronary artery disease and lipid handling, with extra context around blood pressure timing and a lipid-lowering medication response model.
At the same time, several signals are favorable, including high protective cholesterol context, low clotting-related signals, lower heart-failure context, and favorable heart-structure context. That means this is best read as a review category rather than a conclusion that heart disease is likely.
The medication-processing evidence matters if a statin is ever considered, because one transporter pathway can affect how some statins are handled. That does not mean a statin is needed now; it means prescribing choices should use the genetic medication information if the situation arises.
This category becomes worth discussing if there is early heart disease in close relatives, future high blood pressure or cholesterol results, chest symptoms, unexplained exercise limitation, or if a clinician is considering cholesterol medication.
What to watch forKeep routine blood-pressure and lipid prevention on schedule, and make sure the statin-handling result is considered if cholesterol medication is ever discussed.
Show technical evidence
Risk-score evidence
- coronary artery disease: risk percentile 91.9%, coverage 98%, PGS000058.
- high blood pressure age at diagnosis: risk percentile 97.1%, coverage 88%, PGS000935.
- apolipoprotein a: risk percentile 97%, coverage 100%, PGS001888.
- hdl cholesterol mmol l: risk percentile 0.7000000000000028%, coverage 93%, PGS000686.
- congestive heart failure nonhypertensive: risk percentile 12.1%, coverage 100%, PGS001842.
- left ventricular mass index: risk percentile 12.2%, coverage 100%, PGS003427.
Candidate variants
- Variant rs10402271 TT: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
- Variant rs10105606 CC: snpedia_context.
Medication-response context
- SLCO1B1: Decreased Function, *14/*15; affected medicines include Simvastatin (myopathy risk), Atorvastatin, Rosuvastatin, Pravastatin.
Eye, retina, and hearing context
near-term focus
The eye evidence is one of the clearest clusters, especially around retina, detachment-style signals, vision correction, and myopia context, while glaucoma and cataract context is favorable.
Full explanation
The strongest sensory theme is eye-related. Several independent signals point toward retina, retinal detachment or break context, vision correction, and spherical-power or myopia-related traits.
This does not mean an eye condition is present. It does mean eye symptoms should be taken seriously, and routine eye care has more value than it might in a profile without this cluster.
The overall eye picture is not uniformly unfavorable. Glaucoma, eye-pressure, and cataract signals are more protective, so the pattern is more retina and refraction focused than a broad eye-disease pattern.
This category becomes worth reviewing promptly if there are new flashes, floaters, a curtain-like change in vision, sudden vision change, eye trauma, strong family history of retinal disease, or persistent hearing difficulty.
What to watch forTreat new retina-like vision changes as prompt-review events, and keep routine eye exams and hearing review tied to real symptoms or family history.
Show technical evidence
Risk-score evidence
- retinal disorders in diseases classified elsewhere: risk percentile 99.8%, coverage 80%, PGS001276.
- retinal detachments and defects: risk percentile 91.6%, coverage 100%, PGS001833.
- retinal detachments and breaks: risk percentile 90%, coverage 85%, PGS000990.
- diabetic eye disease: risk percentile 91.4%, coverage 80%, PGS001028.
- wears glasses or contact lenses: risk percentile 92.9%, coverage 100%, PGS001924.
- spherical power: risk percentile 82.5%, coverage 93%, PGS001100.
Candidate variants
- Variant rs10089517 CC: snpedia_context.
- HTRA1 rs11200638 GG: snpedia_context; Age related macular degeneration 7.
Gallbladder and digestive-load context
useful to review
Gallstone and gallbladder inflammation signals are very consistent, with digestion-related protein and metabolite context supporting a practical food-tolerance and review category.
Full explanation
Gallbladder-related evidence is unusually consistent. The strongest signals point toward gallstones, gallbladder inflammation, and related bile-handling context.
This is not the same as saying gallstones are present. Genetics can make a body more or less likely to handle bile, fat intake, and digestive load in certain ways, but actual symptoms and imaging determine whether a gallbladder problem exists.
The protein and variant context adds digestion, enzyme, liver-enzyme, fatty-acid, and metabolite background. That makes this useful for diet design, especially avoiding large swings in meal composition.
This category becomes worth discussing if there is right-upper-abdominal pain after meals, nausea after fatty meals, unexplained digestive episodes, abnormal liver or gallbladder testing, or a strong family history of gallstones.
What to watch forUse steady, fiber-rich meals with moderate fat rather than large high-fat swings, and review gallbladder context if meal-triggered upper-abdominal symptoms occur.
Show technical evidence
Risk-score evidence
- gallstones: risk percentile 97.7%, coverage 91%, PGS001256.
- cholecystitis: risk percentile 97.6%, coverage 88%, PGS000942.
- cholelithiasis: risk percentile 96.8%, coverage 92%, PGS001174.
- alanine aminotransferase: risk percentile 5%, coverage 100%, PGS001940.
- other chronic nonalcoholic liver disease: risk percentile 9.5%, coverage 100%, PGS001860.
Protein pathway context
- PNLIPRP2: predicted level percentile 98.9%, R2 0.7241; pathway context only.
- PLB1: predicted level percentile 95.1%, R2 0.5555; pathway context only.
- MEP1B: predicted level percentile 6.6%, R2 0.6752; pathway context only.
- TREH: predicted level percentile 12.3%, R2 0.5404; pathway context only.
Candidate variants
- MIR22,MIR22HG,WDR81 rs11078597 TT: snpedia_context.
- LOC107984063 rs10211524 GG: snpedia_context.
- APOA1-AS,SIK3 rs10047462 TT: snpedia_context.
Immune, gut, and skin inflammation context
useful to review
Immune evidence is broad and mixed, with signals around eosinophils, inflammatory bowel traits, celiac context, psoriasis, sarcoidosis, mouth ulcers, and respiratory infection, plus several protective atopy and rheumatoid signals.
Full explanation
The immune system evidence is one of the broadest clusters in the report. It includes gut inflammation, skin inflammation, eosinophil-related activity, respiratory infection context, mouth-ulcer context, and several immune-cell signaling proteins.
The direction is mixed rather than uniformly risky. Some inflammatory categories are elevated, while rheumatoid arthritis and atopic eczema signals are more favorable. Several immune proteins are also at opposite tails, which suggests immune tuning rather than one simple overactive-or-underactive story.
This category is useful because immune, gut, skin, and airway symptoms often overlap in real life. The genetic evidence supports paying attention to patterns across those systems rather than treating each one as isolated.
This category becomes worth discussing if there are persistent bowel changes, recurrent mouth ulcers, unexplained rashes, psoriasis-like skin changes, repeated infections, wheeze or allergy-like symptoms, abnormal inflammatory markers, or close family history of autoimmune disease.
What to watch forLook for repeated patterns across gut, skin, mouth, and airway symptoms, and use real symptoms or abnormal labs as the trigger for clinical review.
Show technical evidence
Risk-score evidence
- eosinophil percentage: risk percentile 97.9%, coverage 96%, PGS003944.
- crohn s disease: risk percentile 95.4%, coverage 83%, PGS001331.
- inflammatory bowel disease: risk percentile 88.1%, coverage 100%, PGS004013.
- celiac disease: risk percentile 86.5%, coverage 100%, PGS001856.
- psoriasis: risk percentile 90.9%, coverage 90%, PGS001313.
- sarcoidosis: risk percentile 92.3%, coverage 100%, PGS001872.
Protein pathway context
- LILRA6: predicted level percentile 95.9%, R2 0.5266; pathway context only.
- KIR2DS4: predicted level percentile 95.4%, R2 0.7795; pathway context only.
- IL1RAP: predicted level percentile 92.9%, R2 0.706; pathway context only.
- MBL2: predicted level percentile 86.5%, R2 0.6024; pathway context only.
- C1QTNF9: predicted level percentile 90.2%, R2 0.5406; pathway context only.
- TLR3: predicted level percentile 4.3%, R2 0.8019; pathway context only.
Candidate variants
- IL23R rs11209026 GG: snpedia_context.
- LOC105369984 rs10774624 GG: snpedia_context.
- Variant rs10484561 TT: snpedia_context.
- LOC101929727 rs10509540 TT: snpedia_context.
- SQRDL rs1044032 TT: snpedia_context.
Metabolic body-composition and glucose divergence
useful to review
Metabolic evidence is not one-directional: low body-size and adiposity signals are very favorable, while low energy-use, waist-ratio, hypoglycemia, and some diabetes-related signals add practical context.
Full explanation
Your metabolic evidence is strongly divergent. Several body-size, waist, weight, fat-mass, obesity, and glucose-control signals are favorable, which is a meaningful protective pattern.
At the same time, a low energy-use signal, waist-ratio context, hypoglycemia context, and some diabetes-related evidence keep metabolism in the report. This looks less like a simple high-adiposity profile and more like a body-composition and energy-stability profile.
Digestive and metabolic protein evidence adds context around fat digestion, enzyme activity, carbohydrate handling, and metabolite pathways. That supports a steady-food, steady-training approach rather than extreme dieting.
This category becomes worth discussing if future glucose markers shift, there are recurrent low-energy or shaky episodes, unexplained weight change, changes in waist pattern, or performance drops that seem linked to meal timing.
What to watch forPrioritize steady meal timing, fiber-rich carbohydrates, adequate protein, and progressive training; review the pattern if glucose labs or energy stability change.
Show technical evidence
Risk-score evidence
- basal metabolic rate: risk percentile 98.7%, coverage 96%, PGS003903.
- weight: risk percentile 0.7%, coverage 96%, PGS003898.
- arm fat mass: risk percentile 0.1%, coverage 97%, PGS003919.
- obesity: risk percentile 1.4%, coverage 96%, PGS003959.
- incident type 2 diabetes: risk percentile 0.1%, coverage 99%, PGS002779.
- diabetes: risk percentile 82.8%, coverage 90%, PGS001327.
Protein pathway context
- PNLIPRP2: predicted level percentile 98.9%, R2 0.7241; pathway context only.
- PLB1: predicted level percentile 95.1%, R2 0.5555; pathway context only.
- XPNPEP2: predicted level percentile 1.3%, R2 0.5305; pathway context only.
- MEP1B: predicted level percentile 6.6%, R2 0.6752; pathway context only.
- TREH: predicted level percentile 12.3%, R2 0.5404; pathway context only.
- INSL3: predicted level percentile 84.3%, R2 0.7312; pathway context only.
Candidate variants
- Variant rs10105606 CC: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
- LOC107984063 rs10211524 GG: snpedia_context.
- Variant rs10089517 CC: snpedia_context.
- APOA1-AS,SIK3 rs10047462 TT: snpedia_context.
Kidney, fluid, and blood-cell context
useful to review
Kidney-function, creatinine, urine potassium, water-intake, total-protein, red-cell, and platelet evidence forms a lab-awareness cluster rather than a current diagnosis.
Full explanation
A cluster of evidence points toward kidney, fluid, and blood-cell laboratory context. The signals include kidney-function traits, creatinine context, urine potassium, water intake, total protein, red-cell distribution, cell-volume context, platelets, and hemoglobin context.
The evidence is best treated as lab awareness. Genetics can influence where routine markers tend to sit, but only real measurements can say whether kidney function, electrolytes, blood counts, or hydration status are normal.
Protein and variant evidence supports kidney and blood-cell pathway context, including kidney-related immune biology and red-cell traits. This is useful because kidney, blood pressure, fluid balance, and blood counts can interact.
This category becomes worth discussing if future kidney markers, electrolytes, urine findings, blood pressure, blood counts, swelling, or unexplained fatigue are abnormal or changing.
What to watch forUse routine labs and blood pressure as the reality check, and review this category if kidney, electrolyte, urine, or blood-count results move out of range.
Show technical evidence
Risk-score evidence
- chronic kidney disease: risk percentile 92.4%, coverage 100%, PGS004004.
- creatinine: risk percentile 92.6%, coverage 100%, PGS001945.
- potassium in urine: risk percentile 92.9%, coverage 100%, PGS001974.
- water intake: risk percentile 97.6%, coverage 100%, PGS002011.
- total protein: risk percentile 90.8%, coverage 100%, PGS002001.
- red blood celldistribution width: risk percentile 88.6%, coverage 100%, PGS001908.
Protein pathway context
- LCP1: predicted level percentile 2.2%, R2 0.5128; pathway context only.
- HBZ: predicted level percentile 93.8%, R2 0.5431; pathway context only.
- MBL2: predicted level percentile 86.5%, R2 0.6024; pathway context only.
Candidate variants
- LOC107986166 rs10937329 TT: snpedia_context.
- ATP2B4 rs10900585 TT: snpedia_context.
Brain, headache, mood, and sleep-wake context
background
The brain-related evidence includes strong neurodevelopmental context, headache tendency, mood and anxiety-tension signals, chronotype, and research-only brain-region background, balanced by some favorable mood and cognitive-context signals.
Full explanation
The brain and nervous-system evidence is broad. It includes neurodevelopmental context, headaches, mood-related traits, anxiety-tension-related traits, chronotype, and research-only brain-region background.
This should not be read as a diagnosis of autism, depression, anxiety, or any neurological condition. These models describe inherited tendencies and background correlations, not symptoms or clinical status.
Several signals soften the interpretation, including favorable worry, neuroticism, and cognitive-context evidence. That makes this a mixed awareness category rather than a one-way mental-health risk conclusion.
This category becomes worth discussing if headaches become frequent or disabling, sleep timing becomes disruptive, mood or anxiety symptoms persist, concentration changes are new, or there is strong family history of neurological or mood conditions.
What to watch forUse headache frequency, sleep disruption, mood persistence, or family-history context as the trigger for review rather than assuming a condition from genetics alone.
Show technical evidence
Risk-score evidence
- autism spectrum disorder: risk percentile 99.9%, coverage 73%, PGS000327.
- headaches for 3 months: risk percentile 99.7%, coverage 100%, PGS001928.
- suffer from nerves: risk percentile 81%, coverage 90%, PGS001017.
- feelings of worry or anxiety: risk percentile 5.2%, coverage 92%, PGS001021.
- neuroticism score: risk percentile 17.1%, coverage 100%, PGS001996.
- fluid intelligence score: risk percentile 10.099999999999994%, coverage 100%, PGS001919.
Protein pathway context
- ENPP5: predicted level percentile 4.8%, R2 0.6477; pathway context only.
- PSPN: predicted level percentile 11.1%, R2 0.5175; pathway context only.
- DBH: predicted level percentile 83.1%, R2 0.6647; pathway context only.
Candidate variants
- Variant rs10105606 CC: snpedia_context.
Respiratory and sleep-breathing context
background
Snoring, lung-function, and lower-respiratory-infection signals connect with immune and lung-surfactant pathway proteins, making sleep quality and respiratory resilience worth background attention.
Full explanation
Respiratory evidence appears through snoring, lung-function context, and lower-respiratory-infection context. These signals overlap with the immune evidence rather than standing completely alone.
The protein evidence includes lung-surfactant and innate-immune pathway context. That supports a practical interpretation: respiratory resilience, sleep quality, and immune response may be connected in this profile.
This does not mean sleep apnea, asthma, or chronic lung disease is present. Genetics can raise the value of paying attention, but symptoms and objective measurements are what matter.
This category becomes worth discussing if snoring is loud or worsening, sleep is unrefreshing, breathing pauses are witnessed, daytime sleepiness appears, exercise breathing changes, or respiratory infections become unusually frequent or severe.
What to watch forTreat persistent snoring, unrefreshing sleep, daytime sleepiness, or repeated respiratory issues as practical triggers for review.
Show technical evidence
Risk-score evidence
- snoring: risk percentile 96.6%, coverage 100%, PGS002006.
- lung function: risk percentile 88.6%, coverage 93%, PGS001237.
- unspecified acute lower respiratory infection: risk percentile 91.1%, coverage 86%, PGS000925.
Protein pathway context
- SFTPD: predicted level percentile 10.7%, R2 0.5378; pathway context only.
- TLR3: predicted level percentile 4.3%, R2 0.8019; pathway context only.
- MBL2: predicted level percentile 86.5%, R2 0.6024; pathway context only.
- KIR2DS4: predicted level percentile 95.4%, R2 0.7795; pathway context only.
- TPSAB1: predicted level percentile 4.4%, R2 0.5954; pathway context only.
Candidate variants
- LOC105369984 rs10774624 GG: snpedia_context.
Alcohol, nicotine, and risk-taking context
background
Alcohol-use, increased-consumption, early-cigarette, and risk-taking signals are elevated, while one alcohol-status signal is favorable, so the useful takeaway is guardrails rather than diagnosis.
Full explanation
The behavior-related evidence includes alcohol-use tendency, increased alcohol consumption compared with earlier life, time-to-first-cigarette context, and risk-taking behavior. These are tendency signals, not evidence of current habits.
One alcohol-related signal is favorable, so this is not a uniform high-risk pattern. The practical point is that habits can drift under stress, social pressure, or routine change, and genetics can make guardrails more useful.
This category is most useful when it is translated into simple rules: clear weekly limits, avoiding escalation during stress, and being cautious with nicotine exposure if it is not already part of life.
This category becomes worth discussing if alcohol intake increases, control feels harder than expected, nicotine use starts or escalates, risk-taking begins causing real-world consequences, or there is close family history of substance-use problems.
What to watch forSet personal guardrails around alcohol and nicotine exposure, especially during stress or routine change, and review the pattern if control or consequences shift.
Show technical evidence
Risk-score evidence
- alcohol use disorder: risk percentile 98%, coverage 100%, PGS002739.
- increased alcohol consumption versus 10 years ago: risk percentile 95.7%, coverage 87%, PGS001085.
- alcohol drinker status: risk percentile 17.7%, coverage 100%, PGS001901.
- risk taking behaviour: risk percentile 90.3%, coverage 91%, PGS001049.
- time from waking to first cigarette: risk percentile 88.6%, coverage 84%, PGS001532.
Protein pathway context
- DBH: predicted level percentile 83.1%, R2 0.6647; pathway context only.
Colon-polyp and cancer-background context
background
Colon-polyp and benign colon-neoplasm signals are notable, with colorectal and prostate variant context and several cancer-pathway proteins; other cancer signals are protective or background-only.
Full explanation
The strongest cancer-adjacent theme is colon-polyp and benign colon-neoplasm context. There is also colorectal variant context and broader cancer-pathway protein background.
This should not be read as a cancer prediction. Many of these signals are common inherited associations, and several cancer-related signals in the evidence are actually favorable or not directly actionable.
The useful interpretation is screening context. Genetics can make standard age-based screening and family-history conversations more important, but it does not replace clinical guidelines.
This category becomes worth discussing if there is rectal bleeding, persistent bowel-pattern change, unexplained weight loss, iron-deficiency findings, strong family history of colon or prostate cancer, or when age-based screening decisions come up.
What to watch forUse standard age and family-history screening guidance seriously, and review earlier if bowel changes, bleeding, iron-related findings, or strong family history are present.
Show technical evidence
Risk-score evidence
- anal and rectal polyp: risk percentile 91.2%, coverage 100%, PGS001859.
- benign neoplasm of colon: risk percentile 91%, coverage 100%, PGS001811.
- lymphocytic leukemia: risk percentile 2.5%, coverage 99%, PGS000077.
- male genital tract cancer: risk percentile 4.7%, coverage 69%, PGS001111.
- testicular cancer: risk percentile 12.3%, coverage 71%, PGS001164.
- number of self reported cancers: risk percentile 14.2%, coverage 88%, PGS001005.
Protein pathway context
- CEACAM21: predicted level percentile 95%, R2 0.6663; pathway context only.
- TDGF1: predicted level percentile 86.5%, R2 0.7616; pathway context only.
- KLK12: predicted level percentile 0.7%, R2 0.7889; pathway context only.
Candidate variants
- Intergenic rs10795668 GG: snpedia_context.
- Variant rs10505483 CC: snpedia_context.
- Variant rs10484561 TT: snpedia_context.
Training load, joints, and tendon-bursa context
background
A tendon-bursa cyst signal appears, but knee, hip, arthritis, and arthropathy signals are favorable, pointing to progressive loading rather than avoidance.
Full explanation
Musculoskeletal evidence is mixed but generally practical. One signal points toward ganglion or tendon-bursa cyst context, which is the kind of finding that can show up around repetitive loading or local irritation.
Several other joint-related signals are favorable, including knee, hip, arthritis, and broader arthropathy context. That argues against treating the profile as fragile.
The training implication is to build capacity gradually. Strength, mobility, and load management are more useful than avoiding exercise because of genetics.
This category becomes worth reviewing if a lump near a tendon or joint appears, joint swelling persists, pain changes mechanics, training load jumps quickly, or repeated overuse symptoms affect performance.
What to watch forUse progressive strength and mobility work, increase load gradually, and review persistent tendon or joint swelling rather than training through it.
Show technical evidence
Risk-score evidence
- ganglion and cyst of synovium tendon and bursa: risk percentile 96.7%, coverage 100%, PGS001879.
- internal derangement of knee: risk percentile 1.9%, coverage 83%, PGS001027.
- arthritis: risk percentile 19.6%, coverage 88%, PGS001135.
- coxarthrosis arthrosis of hip: risk percentile 17.5%, coverage 88%, PGS000967.
- other arthropathies: risk percentile 14.2%, coverage 100%, PGS001877.
- impedance of arm: risk percentile 86%, coverage 97%, PGS003908.
Protein pathway context
- AFAP1: predicted level percentile 97%, R2 0.5176; pathway context only.
- ICAM2: predicted level percentile 84%, R2 0.5536; pathway context only.
Medication Safety
Genes below have pharmacogenomic phenotypes that may affect drug choice or dose review. Use this as a clinical discussion aid, not as a standalone prescribing instruction.
CYP2C9
INTERMEDIATE METABOLIZER
*1/*2
Affected drugs: Warfarin, Phenytoin, Celecoxib, Flurbiprofen, Losartan, Simvastatin
CYP3A5
POOR METABOLIZER
*3/*3
Affected drugs: Tacrolimus, Sirolimus
SLCO1B1
DECREASED FUNCTION
*14/*15
Affected drugs: Simvastatin (myopathy risk), Atorvastatin, Rosuvastatin, Pravastatin
This report comes from consumer microarray data with statistical imputation. Confirm clinically before changing prescriptions.